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Genetic Susceptibility to Atopic
Dermatitis
Chikako Kiyohara1, Keiko Tanaka2 and Yoshihiro Miyake2
ABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with an increasing prevalence in industrialized
countries. AD belongs to the group of allergic disorders that includes food allergy, allergic rhinitis, and asthma.
A multifactorial background for AD has been suggested, with genetic as well as environmental factors influenc-
ing disease development. Recent breakthroughs in genetic methodology have greatly augmented our under-
standing of the contribution of genetics to susceptibility to AD. A candidate gene association study is a general
approach to identify susceptibility genes. Fifty three candidate gene studies (50 genes) have identified 19
genes associated with AD risk in at least one study. Significant associations between single nucleotide poly-
morphisms (SNPs) in chemokines (chymase 1―1903A > G), cytokines (interleukin13 Arg144Gln), cytokine re-
ceptors (interleukin 4 receptor 1727 G > A) and SPINK 1258 G > A have been replicated in more than one
studies. These SNPs may be promising for identifying at-risk individuals. SNPs, even those not strongly associ-
ated with AD, should be considered potentially important because AD is a common disease. Even a small in-
crease in risk can translate to a large number of AD cases. Consortia and international collaborative studies,
which may maximize study efficacy and overcome the limitations of individual studies, are needed to help fur-
ther illuminate the complex landscape of AD risk and genetic variations.
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INTRODUCTION
The atopic diseases, particularly atopic dermatitis,
food allergy, asthma and hay fever, are among the
most common chronic diseases. The prevalence of
atopic diseases has increased to epidemic dimensions
over the past decades. In industrialized countries, 25―
30% of the population is affected. Atopic diseases are
a major cause of illness and disability and represent
an important public health issue accounting for a
large proportion of health care spending. Atopic der-
matitis (eczema) is a chronic inflammatory skin dis-
ease with onset typically in early childhood and is the
most common chronic inflammatory skin disease in
children in industrialized countries.1 For example,
the prevalence of atopic dermatitis among schoolchil-
dren is 21.1% in Japan,2 17.2% in the US3 and 15.6% in
Northern European countries.4 It is commonly the in-
itial clinical manifestation of allergic disease, often
preceding the onset of respiratory allergies.5 Along
with asthma and allergic rhinitis, atopic dermatitis is
an important manifestation of atopy that is character-
ized by the formation of allergy antibodies (IgE) to
environmental allergens. In developed countries, the
prevalence of atopic dermatitis is approximately 15%,
with a steady increase over the past decades.6,7 While
many environmental components have been studied
for years, significant progress has been made only re-
cently in identifying the genes responsible for suscep-
tibility of atopic diseases. In order to identify suscepti-
bility genes for AD, two general approaches, genome-
wide screens and candidate gene association studies,
have been used. In candidate gene association stud-
ies, variations in known genes whose biological func-
tions implicate them in the pathophysiology are com-
pared between unrelated cases and controls. Signifi-
cantly higher frequencies of alleles at candidate loci
in cases compared with controls may indicate a
causal relationship between the marker allele and the
disease. In general, association studies are easier to
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Table 1 Candidate Genes for Atopic Dermatitis
LocusGene NameGene Symbol
Patern Recognition Receptors
7p15-p14caspase recruitment domain-containing protein 4CARD4 (NOD1)
16q21caspase recruitment domain-containing protein 15CARD15 (NOD2)
5q31.1monocyte diferentiation antigen CD14CD14
10q11.2-q21lectin, mannose-binding, soluble, 2MBL2
4q32Tol-like receptor 2 TLR2
9q32-q33Tol-like receptor 4 TLR4
4p14Tol-like receptor 6 TLR6
Chemokines and Associated Molecules
17q11.2-q12chemokine (C-C motif) lagand 2CCL2 (MCP-1)
17q11.2-q12chemokine (C-C motif) ligand 5CCL5 (RANTES)
17q21.1-q21.2chemokine (C-C motif) ligand 11CCL11 (Eotaxin)
16q13chemokine (C-C motif) ligand 17CCL17 (TARC)
3p21.3chemokine (C-C motif) receptor 3CCR3
3p24chemokine (C-C motif) receptor 4CCR4
14q11.2chymase 1CMA1
Cytokines and Associated Molecules
2q14.2interleukin 1 receptor antagonistIL1RN
2q11.2interleukin 1 receptor-like 1IL1RL1 (ST2)
2q14interleukin 1, alphaIL1A
2q14interleukin 1, betaIL1B
5q31.1interleukin 4IL4
16p12.1-p11.2interleukin 4 receptorIL4R
5q31.1interleukin 5IL5
7q21interleukin 6IL6
1q31-q32interleukin 10IL10
5q31.1-q33.1interleukin 12, betaIL12B
19p13.1interleukin 12 receptor, beta-1IL12RB1
5q31interleukin 13IL13
11q22.2-q22.3interleukin 18IL18
19q13.1transforming growth factor, beta-1TGFβ1
6p21.3tumor necrosis factor, alphaTNFα
5q31.1granulocyte-macrophage colony-stimulating factor 2GM-CSF (CSF2)
12q13signal transducer and activator of transcription 6STAT6
12q14interferon, gammaIFNγ
Antigen Presentation Molecules
6p21.3major histocompatibility complex, class I, AHLA-A
6p21.3major histocompatibility complex, class I, BHLA-B
6p21.3major histocompatibility complex, class I, DM alphaHLA-DMA
6p21.3major histocompatibility complex, class I, DM betaHLA-DMB
6p21.3proteasome subunit, beta-type, 8PSMB8 (LMP7)
6p21.3proteasome subunit, beta-type, 9PSMB9 (LMP2)
6p21.3transporter, ATP-binding cassete, major histocompatibility complex, 1TAP1
6p21.3transporter, ATP-binding cassete, major histocompatibility complex, 2TAP2
Others
2q33cytotoxic T lymphocyte-associated 4CTLA4
19q13.33kalikrein 7KLK7 (SCCE)
17q25runt-related transcription factor1 binding site between solute carier 
family 9, isoform 3 regulatory factor 1 and N-acetyltransferase 9
RUNX1 binding site between 
SLC9A3R1- NAT9
5q32serine protease inhibitor, Kazal-type, 5SPINK5
Drug-Metabolizing Enzymes
11q13glutathione s-transferase, piGSTP1
1p13.3glutathione s-transferase, mu-1GSTM1
22q11.2glutathione s-transferase, theta-1GSTT1
8p23.1-p21.3N-acetyltransferase 2NAT2
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perform than genome-wide screens because they do
not require the collection of family material. Genetic
and environmental factors determine disease suscep-
tibility8 and twin studies indicate that the genetic con-
tribution is substantial.9 Research on genetic and en-
vironmental relationships is necessary for better un-
derstanding AD susceptibility.
The objective of this review paper is to review dis-
ease genes and to contribute to our understanding of
how genetic variation causes atopic dermatitis.
METHODS
To evaluate candidate genes, we conducted MED-
LINE, Current Contents and Web of Science
searches of papers published before August 2006 us-
ing “atopic dermatitis (eczema)” and “polymorphism”
as keywords. Additional articles were identified
through the references cited in the first series of arti-
cles. Using the MEDLINE database, we identified 48
studies that provided information on atopic dermatitis
occurrence associated with genetic polymorphisms.
No additional articles through other databases were
identified.
SNP ANALYSIS AND ATOPIC DERMATITIS
(Tables 1, 2)
PATTERN-RECOGNITION RECEPTORS
The specificity of the adaptive immune response,
which is mediated by T and B cells, occurs through
somatic mutation and the selection of receptors that
best recognize microbial antigens. In contrast, the in-
nate immune response relies on evolutionary ancient
germline-encoded receptors, pattern-recognition re-
ceptors. These receptors recognize highly conserved
microbial structures, enabling the host to recognize a
broad range of pathogens quickly, without the need
for time-consuming somatic mutation.10 These micro-
bial structures, known as pathogen-assocaited mo-
lecular patterns, are generally essential for the sur-
vival of the microorganism and, as such, are immuta-
ble.
The ability of the innate immune system to distin-
guish between pathogens has been of considerable
interest in the past few years, and recent discoveries
have led to some fundamental breakthroughs, al-
though much is still not understood. The discovery of
the Toll-like receptors (TLRs), in particular, has given
an insight into the mechanisms of intracellular signal-
ling after microbial sensing and initiation of protec-
tive immune responses. Recent progress has re-
vealed that innate immune responses are initiated by
various TLRs.11 TLRs comprise a family of proteins
that enhance certain cytokine gene transcription in
response to various pathogenic ligands and control
acquired immune responses such as Th1 res-
ponses.12,13 TLR4 is a receptor for lipopolysaccharide
(LPS).14,15 Recent studies on mouse16-18 and human19
mast cells suggest that LPS-induced activation is me-
diated through TLR4 expressed on mast cells. A pro-
tective role for mast cells in bacterial infection was
first addressed in a bacterial peritonitis animal model,
and infection is suggested to be mediated by the pro-
duction of TNFα as a consequence of TLR4 activa-
tion.20-22 More recently, LPS-induced production of
inflammatory cytokines (IL-1β, TNF-α, IL-6, and IL-
13) from mast cells in the peritoneal cavity and the re-
sulting neutrophil recruitment have been suggested
to be important for protection in septic peritonitis.22
In addition, TNFα produced by mast cells is involved
in hypertrophy of draining lymph nodes during in-
tradermal bacterial infection.23 However, the conse-
quences of LPS-induced mast-cell activation in aller-
gic airway inflammation are not well elucidated. Al-
though the role of the non-TLR pattern-recognition
receptors (CARD4, CARD15, CD14, MBL2) is gener-
ally less well-appreciated, it is becoming increasingly
clear that these receptors also play key roles in initiat-
ing an innate immune response.
CARD4 (NOD1) maps on chromosome 7p15―p14.
It covers 54.49 kb on the reverse strand. Eleven
CARD4 (NOD1) SNPs, such as rs2736726 (A > G),
rs2075817 (A > G), rs2975632 (C > T), rs3030207 (A >
G), rs2075818 (C > G), rs2235099 (C > T), rs2075821
(A > G), rs2075822 (C > T), rs2907749 (A > G),
rs2907718 (C > T), rs5743368 (A > G), were investi-
gated in a German population. Genotypes AA at
rs2736726 and GG at rs2075817 were weakly protec-
tive for AD, with odds ratios (ORs) of 0.41 (95% CI =
0.18―0.94) and 0.43 (95% CI = 0.18―0.99), respec-
tively.24 It has been also observed that haplotype rs
2736726 A- rs2075817 G - rs2975632 T- rs3030207 A-
rs2075818 C- rs2235099 C- rs2075821 G - rs2075822
T- rs2907749 A- rs2907718 C- rs5743368 G is weakly
associated with atopic eczema (OR = 0.260, 95% CI =
0.07―0.92).24
CARD15 (NOD2) maps on chromosome 16q21. It
covers 39.45 kb on the direct strand. No significant
associations between AD and any SNP (2104C > T,
2722 G > C, 802T > C, 534 G > C, rs1077861 (intron
10A > T), 2863 G > A, 4278A > G, -60A > G) or haplo-
type of CARD15 were observed.25 Associations of
three SNPs (2104C > T, 2722 G > C and 3020iC) with
AD in children have been reported. Children with the
C allele of 2722 G > C SNP had a 1.85-fold risk (95%
confidence interval (CI) = 1.10―3.13) of developing
AD.26
CD14 maps on chromosome 5q22―q32. It covers
1.95 kb on the reverse strand. In a small study, chil-
dren with the CT genotype of the CD14−159C > T
SNP had a significantly lower prevalence (p = 0.017)
of AD at three years of age compared with those with
the genotypes CC and TT combined,27 although the
CD14-159C > T SNP was not associated with an in-
creased risk of AD in German children.28 No signifi-
cant difference was found in the genotype frequen-
cies of -159C > T, -1145 G > A, -1359 G > T and
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Ref.SNPGene symbol
Patern-Recognition Receptors
24haplotype (rs2736726 (A＞G), rs2075817 (A＞G), rs2975632 (C＞T), 
rs3030207 (A＞G), rs2075818 (C＞G), rs2235099 (C＞T), rs2075821 (A＞G), 
rs2075822 (C＞T), rs2907749 (A＞G), rs2907718 (C＞T), rs5743368 (A＞G)
CARD4 (NOD1)
25, 26－ 60A＞ G, 534G＞ C, 802T＞ C, 2104C＞ T, 2722G＞ C, rs1077861 
(intron10A＞T), 2863G＞A, 4278A＞G, 3020iC
CARD15 (NOD2)
27, 28, 29－1145G＞A, －1359G＞T, －550C＞T, －159C＞TCD14
30Gly54AspMBL2
31, 32rs5743708 (A＞G), rs4696480 (T＞A), rs3804099 (T＞C), rs3804100 (T＞C)TLR2
31, 32rs4986790 (A＞G), rs4986791 (C＞T), rs2770150 (T＞C), rs6478317 (A＞G), 
rs1927911 (C＞T), rs2149356 (C＞T), rs7873784 (G＞C), rs1927906 (A＞G)
TLR4
33rs5743810 (T＞C)TLR6
Chemokines and Associated Molecules
63－2518A＞GCCL2 (MCP-1)
63, 64－403G＞A, －401G＞A, －28C＞GCCL5 (RANTES)
67－426C＞T, －384A＞G, 67G＞ACCL11 (Eotaxin)
71－431C＞TCCL17 (TARC)
7551T＞CCCR3
761014C＞TCCR4
77, 78, 79, 80, 
81, 82
－1903A＞GCMA1
Cytokines and Associated Molecules
100penta-alelic 86-bp tandem repeat in intron 2IL1RN
101－26999G＞A, －27639A＞G, 744C＞A, 11147C＞T, 2992C＞T, 5283G＞A, 
5860C＞A
IL1RL1 (ST2)
102－899T＞CIL1A
100,102, 103－1418T＞C, －511T＞C, 315T＞C, 3953T＞CIL1B
104, 105, 106－590T＞C, －589C＞T, 33T＞CIL4
106, 107, 108, 109－ 3112C＞ T, － 1803T＞ C, － 327C＞ A, － 326A＞ C, － 186G＞ A, 
223C＞G＞T＞A, 1199C＞A, 1291C＞T, 1242T＞G, 1307T＞C, 
1507C＞T, 1727G＞A, 2356C＞T
IL4R
110－703C＞TIL5
100, 102－922A＞G, －174C＞GIL6
100, 102, 106－1117G＞A, －1082G＞A, －854C＞T, －819T＞C, －592A＞C, －571C＞AIL10
106, 1111188A＞C, 4237G＞A, 4496A＞G, 4510G＞AIL12B
112－111A＞T, －2C＞T, 4443C＞T, 5970G＞C, 17183T＞C, 17369C＞T, 
25748T＞C, 27637A＞T
IL12RB1
102, 105, 106, 
113, 114, 115
－1111C＞T, －1024C＞T, 704A＞C, 1103C＞T, Arg144Gln, 1293C＞TIL13
116－137G＞C, －133C＞G, －132A＞G, 113T＞G, 127C＞TIL18
102, 117－590C＞T, 869C＞T, 915G＞CTGFβ1
100, 102, 103, 106－1031T＞C, －863C＞A, －857C＞T, －308G＞A, －238G＞A TNFα
103, 119－1916T＞C, －677C＞A, 3606T＞C, 3928C＞TGM-CSF (CSF2)
106, 1202964G＞A, 13/14/15/16 GT repeat in exon 1, short tandem repeat in exon 1STAT6
106short tandem repeat in intron 1IFNγ
(Continued)
Table 2 Polymorphisms of Candidate Genes for Atopic Dermatitis
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Ref.SNPGene symbol
Antigen-Presentation Molecules
1301, 2, 3, 11, 24, 26, 29, 30, 31, 33, 66HLA-A
1307, 8, 13, 14, 16, 27, 35, 37, 38, 39, 46, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 
61, 62, 67, 71, 75
HLA-B
131Val140Ile, Gly155Ala, Ile179Thr, 184Arg-His-CysHLA-DMA
131144Ala-Glu-ValHLA-DMB
1303911G＞T, 3912C＞T, 4069C＞TPSMB8 (LMP7)
130Arg60HisPSMB9 (LMP2)
130, 136Val333Ile, Gly637AspTAP1
130Ile379Val, Thr565Ala, Ala665Thr, Gln687StopTAP2
Others
15949A＞GCTLA4
170AACC insertionKLK7 (SCCE)
171rs734232 (G＞A)RUNX1 binding site 
between
SLC9A3R1- NAT9
173, 174
175 (175),176, 
177
IVS12－26C＞T, IVS12－10A＞G, IVS14＋19G＞A, IVS13－50G＞A, 
1103A＞G, 1156G＞A, 1188T＞C, 1258G＞A,
Asp106Asn, Gly463Gly, Val553Val, Leu756Leu, Gly804Gly
SPINK5
Drug-Metabolizing Enzymes
1891404A＞G, 2294C＞TGSTP1
189Deletion polymorphism (non-nul or nul genotype)GSTM1
189Deletion polymorphism (non-nul or nul genotype)GSTT1
195, 196481C＞T, 590G＞A, 857G＞ANAT2
Disease susceptible SNPs found to be significant in one study and the coresponding references are single-underlined.
Disease susceptible SNPs found to be significant at least in two independent studies and the coresponding references are double-
underlined.
Table 2 (Continued)
-550C > T SNPs between AD patients and controls.29
MBL2 maps on chromosome 10q11.2―q21. It cov-
ers 6.32 kb on the reverse strand. Recently, three
variants at codons 52, 54, and 57 of exon 1 of the
MBL2 gene have been identified. The MBL2 Gly54
Asp SNP was not associated with an increased risk of
AD in a Japanese population.30
TLR2, TLR4 and TLR6 map on chromosome 4q32,
9q32―q33 and 4p14, respectively. In a German popu-
lation, the TLR2 rs5743708 (A > G) SNP increases the
susceptibility to severe AD while AD patients exhibit
a higher frequency of the TLR4 polymorphisms
rs4986790 (A > G) and rs4986791 (C > T) SNPs.31
However, it has been found that common TLR2
(rs4696480 (T > A), rs3804099 (T > C), rs3804100 (T
> C), rs5713708 (G > A) or TLR4 (rs2770150 (T > C),
rs6478317 (A > G), rs1927911 (C > T), rs2149356 (C >
T), rs4986790 (A > G), rs4986791 (C > T), rs7873784
(G > C), rs1927906 (A > G)) variants or haplotypes
were not associated with an increased risk of AD in
another German population.32 There was no associa-
tion between the TLR6 rs5743810 (T > C) polymor-
phism and risk for AD.33
CHEMOKINES AND RELATED MOLECULES
Chemokines are a group of chemotactic cytokines
that induce inflammatory cell mobilization through a
concentration gradient.34 Chemokines are relevant in
allergy and asthma not only for their role in regulat-
ing leukocyte recruitment, but also for other activi-
ties, such as cellular activation, inflammatory media-
tor release, promotion of Th2 inflammatory re-
sponses, and regulation of IgE synthesis.35 Chemoki-
nes are divided into four classes on the basis of their
protein structure (specifically the location of cysteine
motifs conserved within the N-terminal domain):
CXC, CC, C, and CX3C chemokines. To date, over 50
chemokines have been identified, of which 28 are CC
chemokines, 16 are CXC chemokines, two are C
chemokines (XCL1 and XCL2) and one is a CX3C
(CX3CL1) chemokine.36 The CC and CXC chemoki-
nes are inflammatory chemokines while the C and
CX3C chemokines are immune chemokines. The
chemokines discussed in the remainder of the paper
are CC chemokines. Some chemokines, such as
CCL5 (RANTES), CCL11 (eotaxin), CCL2 (MCP-1),
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CCL8 (MCP-2), CCL7 (MCP-3), CCL13 (MCP-4) and
macrophage inflammatory protein (MIP)-1αCCL3,
cause cellular activation and inflammatory mediator
release by basophils and eosinophils.35 Receptors
CCR1 through CCR10 bind the CC chemokine; re-
ceptors CXCR1 through CXCR6 bind CXC chemoki-
nes; and C and CX3C chemokines bind to XCR1 and
CX3CR1, respectively.36 At least three chemokine re-
ceptors have been shown to mediate the recruitment
of Th2 cells: CCR3, the receptor for CCL5 (RANTES),
CCL11 (eotaxin), CCL2 (MCP-1), and CCL13 (MCP-
4), which is also expressed on eosinophils and baso-
phils;37-39 CCR4, the receptor for CCL17 (TARC) and
CCL22 (MDC); 40,41 and CCR8, the receptor for CCL1
(I-309).42,43
CCL5 (RANTES) has several functions, including
the stimulation of histamine secretion from basophils,
the activation of eosinophils, and the mobilization of
monocytes, eosinophils, and memory TH cells (with
a preference for CD45RO+ and CD4+ subtypes). Al-
though virtually all nucleated blood and tissue cells
produce chemokines, the primary source of cutane-
ous CCL5 (RANTES) appears to be dermal fibro-
blasts. CCL11 (eotaxin 1) is a selective chemoattrac-
tant and activator of both eosinophils44 and TH2 lym-
phocytes, and it might also operate as an indirect
negative regulator of neutrophil recruitment.45,46 En-
hanced levels of both CCL5 (RANTES) and CCL11
(eotaxin 1) have been identified in the sera of patients
with AD,47 with CCL5 (RANTES) demonstrating a
significant positive correlation with both total serum
IgE levels and eosinophil numbers. Eotaxin 1 also
demonstrates a significantly increased pattern of
gene expression in lesional skin biopsy specimens
taken from patients with AD compared with those
from nonatopic control subjects.48 Consistent with a
role for these CC chemokines in the pathology of AD,
tacrolimus (FK506) ointment, a clinically effective
macrolide lactone AD treatment, has been shown to
suppress the expression of both CCL5 (RANTES)
and CCL11 (eotaxin 1) in lesional AD skin.49 UV-B ir-
radiation, used in phototherapy, also inhibits cyto-
kine-stimulated CCL5 (RANTES) expression in cul-
tured epidermal keratinocytes.50 Together these data
indicate that CC chemokines, particularly CCL5
(RANTES) and CCL11 (eotaxin 1), might represent
useful future targets for the genetic dissection of AD.
CCL17 (TARC) is predominantly expressed on Th2
lymphocytes, basophils, and natural killer cells.51-54
Thus, CCL17 is likely to play an important role in
Th2-type immune responses by selectively recruiting
CCR4+ Th2-polarized memoryeffector T cells into in-
flamed tissues. Cutaneous lymphocyte-associated an-
tigen (CLA) is expressed by the vast majority of skin-
infiltrating T cells and is involved in the recruitment
of skin-associated T cells to inflammatory sites by in-
teracting with the endothelial cell ligand E-selectin,
which is highly expressed in inflamed skin.55 Essen-
tially all CLA+ skin-seeking memory effector T cells
express CCR4.56,57
Mast cell chymase (CMA1) is a glycosylated chy-
motryptic-like serine protease that is found at high
levels in the secretory granules of mast cells and ap-
pears to operate in concert with histamine and tryp-
tase to confer a range of proinflammatory effects
upon release from activated cells.58,59 It activates sev-
eral biological mediators, including angiotensin I, IL-
1β, and endothelin-1, by the cleavage of precursor
forms of these molecules.60 The mechanism of
chemokine production by endothelial cells stimulated
with mast cell tryptase is unclear. One possible
mechanism involves activation of protease-activated
receptors (PARs). Tryptase or thrombin cleaves the
amino-terminal extracellular extension of the intact
and inactivated receptor, exposing the amino termi-
nus, which then functions as a receptor agonist, bind-
ing to a region of the receptor and activating it. Four
subtypes of PAR have been cloned. The thrombin
receptor-1 (PAR-1) is expressed on endothelial cells
but does not appear to be activated by tryptase. PAR-2
is also expressed on endothelial cells, and it may be
activated by tryptase.61 The effect of human mast cell
tryptase on endothelial cells inducing the production
of chemokine may be mediated by this receptor.
PAR-3 and PAR-4 can also be cleaved by thrombin.62
However, little is known about the relationship be-
tween tryptase and these receptors.
CC cytokine genes cluster on the q-arm of chromo-
some 17. The CCL2 (MCP-1) -2518A > G SNP has not
been shown to be associated with AD in a Hungarian
cohort.63
CCL5 (RANTES) maps on chromosome 17q11.2―
q12. It covers 9.01 kb on the reverse strand. Two
polymorphisms in the CCL5 (RANTES) promoter re-
gion (-28CG and -403 GA) affect the transcription of
the CCL5 (RANTES) gene.64,65 In human cell lines,
the -28 G allele of -28C > G SNP and the -403 A allele
of -403 G > A SNP increase promoter activity of CCL
5 (RANTES) compared to the more frequent -28C al-
lele and the -403 G allele, respectively, suggesting
that these polymorphisms increase CCL5 (RANTES)
expression in humans.64 In fact, these variations re-
sult in the generation of a novel consensus binding
site for the GATA transcription factor family and has
been associated with enhanced CCL5 (RANTES) pro-
duction in patients with AD.66 The -401A allele of the -
401 G > A SNP was more frequent in AD patients
compared with control subjects in a German popula-
tion (p < 0.037).64 There was no association between -
28C > G and -403 G > A SNPs in the RANTES pro-
moter, and -2518A > G SNP in the distal regulatory re-
gion of the gene and AD in a Hungarian population.63
CCL11 (eotaxin 1) maps on chromosome 17q21.1―
q21.2. It covers 2.66 kb on the direct strand. A num-
ber of polymorphisms have been identified in the
gene. Although the two SNPs (-426C > T, -384A > G)
Genetic Susceptibility to Atopic Dermatitis
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in the promoter region of the CCL11 gene were asso-
ciated with serum IgE levels in AD patients, the two
and 67 G > A SNPs were not shown to be associated
with susceptibility to AD.67 This apparent specificity
of this effect might be related to the diminutive size
of the genotyped sample of this single study,67 the
low magnitude of the underlying genetic effect, and
the power advantage associated with the use of quan-
titative traits. Consequently, these data require repli-
cation, as well as further study in a more substantial
cohort of subjects. An orally available antagonist of
the eotaxin 1 receptor (YM-344031) does, however,
lend some support to the genetic findings because it
has recently been shown to inhibit both immediate
and late-phase antigen-induced cutaneous inflamma-
tion in a mouse model of allergy.68 Significant linkage
disequilibrium was observed between positions -426
and -384, and also between -384 and 67.69
The CCL17 (TARC) maps on chromosome at
16q13. It covers 11.30 kb on the direct strand. The
serum TARC levels of patients with AD were signifi-
cantly elevated and correlated with disease activity,
and immunoreactive TARC levels were detected in
epidermal keratinocytes (KCs), dermal infiltrating
cells, and endothelial cells in acute and chronic le-
sional skin.70 These observations strongly suggest
that KCs can be a source of TARC in the lesional skin
of patients with AD and that KCs producing TARC
may be involved in the pathogenesis of AD. Although
some SNPs of TARC are candidates as a genetic fac-
tor in AD, no association between AD and the -431C >
T SNP of the TARC gene was observed in a Japanese
population.71 The results of the study, however,
should be considered very preliminary due to the
small number of AD patients.
CCR3 maps on chromosome 3p21.3. It covers
143.70 kb on the direct strand. As stated earlier,
CCR3 is a receptor for various chemokines which are
important in the pathogenesis of AD. Therefore, the
biological activities of CCR3 suggest that polymor-
phisms of CCR3may impart an increased risk for AD.
Several SNPs in CCR3 have been reported, including
silent mutations (51T > C72,73 and 240C > T73) and
missense mutations (652T > A,74 824 G > A,72,73 971T
> C,72 1052T > C73). There was no significant differ-
ence in genotype frequencies of 51T > C SNP of the
CCR3 gene between AD patients and controls.75
CCR4 maps on chromosome 3p24. It covers 3.36
kb on the direct strand. There was no significant as-
sociation with the 1014C > T SNP of the CCR4
gene.76
CMA1 maps on chromosome 14q11.2. It covers
2.91 kb on the reverse strand. There have been sev-
eral reports of a significant association between a
CMA1 promoter polymorphism (-1903A > G) and
atopic eczema in Japanese adults and school-
children.77 These results could not be confirmed in
another Japanese study with 100 patients and 69
patient-parents-trios78 and an Italian study with 70 pa-
tients.79 There was also no association between
CMA1-1903A > G genotype and AD risk in Japanese
but there was a significant association between the
CMA1 genotype and AD patients with a serum IgE
concentration of < 500 IUmL.80 Recently, a family-
based association study in Caucasians revealed a sig-
nificant association of this polymorphism with total
IgE levels in patients with self-reported AD.81 As in
the study of Mao et al.,77 a significant association be-
tween the CMA1-1903A > G polymorphism and AD
was observed by Weidinger et al.82 It may be specu-
lated whether this DNA variant alters the expression
of chymase. Recently, it has been shown that CMA1
is increased in chronic atopic eczema skin lesions,83
and a potential role of chymase in the promotion of
skin barrier defects and cutaneous neovascularization
has been suggested.84 Preliminary studies in animal
models have indicated a therapeutic potential of chy-
mase inhibitors in AD.85,86
Ma et al.77 suggested that variants of CMA1 may
have been one source of genetic risk for AD in a Japa-
nese population while other Japanese studies78,80
failed to confirm this association. Functional studies
and analyses of other loci are needed to clarify the
consequences of the -1903A > G polymorphism in the
CMA1 gene and might determine whether chymase
will qualify as a target for therapeutic interventions in
AD.
CYTOKINES
Cytokines have been functionally divided into two
subgroups: Th1 cytokines, mainly interleukin (IL) 2,
IL12, interferon (IFN)γ, and tumor necrosis factor
(TNF)α, which activate the cellular machinery of the
immune system; and Th2 (IL4, IL5, IL6, IL10 and
IL13) cytokines, which activate the humoral machin-
ery.87-90 Unusual deviation of the balance between
Th1 and Th2 results in many immune diseases such
as allergy and autoimmune diseases. Excessive Th1
immune response has been implicated in autoim-
mune diseases such as rheumatoid arthritis and mul-
tiple sclerosis, liver injury and graft versus host dis-
ease while unusual deviation in Th2 immunity causes
allergic diseases and systemic lupus erythematosus.
For example, IL2, mainly secreted by Th1 cells, is
an autocrine stimulator of Th1 cell differentiation and
proliferation resulting in a T cell shift towards the
Th1 phenotype. IL12 is a proinflammatory interleukin
mainly produced by macrophages, B cells, and DCs.
It promotes Th1 cell function while suppressing Th2
cell function. IFNγ can down-regulate allergic airway
inflammation and mucus production,91 further sup-
porting the critical importance of Th2 cells in allergy
and asthma. Of note, airway hyperresponsiveness
(AHR) is induced by the transfer of IL-4-deficient Th2
cells, with a concomitant marked reduction of eosino-
philia. This suggests that Th2 cells can induce AHR
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even via IL4-independent mechanisms, but not by
transfer of Th1 cells. In contrast, Th1 cells induced
neutrophilic inflammation without AHR.92 In another
murine model of acute eosinophilic airway inflamma-
tion, however, Th1 cells were required in addition to
Th2 cells for endogenous eosinophil recruitment,
suggesting that Th2 cells may need Th1-derived sig-
nals for effective recruitment to airways.93 Finally, en-
gineering of Th2 cells to produce latent transforming
growth factor (TGF) β1 reverted allergen-induced
AHR and inflammation, which supports the concept
that TGFβ-producing T cells play an important regu-
latory role in asthma,94 and also that airway fibrosis
and remodelling may be the final consequence of
chronic or repeated TGF-β production. TNFα is ex-
pressed on the cell membrane and is then hydrolyzed
to release the soluble form, which forms homotrim-
ers. TNFβ (LT-α) has no cell membrane attachment
domain but can form either membrane-anchored het-
erotrimers with LT-β or soluble homotrimers.
It is of note that Th2 cytokines can account directly
or indirectly for the great majority of pathophysiologi-
cal manifestations of allergic patients. IL4 is poten-
tially pro-inflammatory and pro-atherogenic and in-
duces circulating eosinophils to roll on and adhere to
endothelial cells.95 These eosinophils can then be at-
tracted to target tissues by both IL-5 and chemokines.
IL10 is a prototype anti-inflammatory interleukin pro-
duced mainly by activated T cells, B cells, and macro-
phages. It was described in mice as a Th2 cytokine
that selectively inhibits IFNγ and granulocyte-
macrophage colony-stimulating factor 2 (GM-CSF or
CSF2) production by the Th1 cells. IL-13 is responsi-
ble for mucus hypersecretion by mucus cells, and in-
duces metaplasia of mucus cells.96 IL4 and IL13
stimulate fibroblast growth and chemotaxis, as well
as the synthesis of extracellular matrix proteins.97,98
However, subepithelial fibrosis in asthma also results
from the activity of TGFβ, produced by T cells,
eosinophils and fibroblasts, as well as of IL-6 pro-
duced by several cell types, including Th2 cells them-
selves.99 Taken together, these findings indicate that
Th2 cytokines, either directly or indirectly, can ac-
count for the hallmarks of allergic inflammation.
IL1RN maps on chromosome 2q14.2. It covers
34.70 kb on the direct strand. The polymorphism in
intron 2 of the IL1RN gene is caused by a variable
copy number of an 86-bp sequence. The 4-repeat
(IL1RN*1) and 2-repeat (IL1RN*2) alleles are most
common, while the other alleles occur at a combined
frequency of less than 5%. No association was found
between the variable number of tandem repeat poly-
morphisms in intron 2 of the IL1RN gene and AD.100
IL1RL1 (ST2) maps on chromosome 2q12. It cov-
ers 40.54 kb on the direct strand. A significant asso-
ciation between AD and the -26999G > A SNP of the
ST2 gene was found in a Japanese population (OR =
1.86, 95% CI = 1.42―2.45).101 On the other hand,
2992C > T, 5283G > A, 5860C > A, 11147C > T, 744C >
A and -27639A > G SNPs were not associated with AD
risk.101
IL1A and IL1B map on chromosome 2q14. The for-
mer covers 11.48 kb on the reverse strand and the
latter covers 7.16 kb on the reverse strand. The
-899T > C SNP of the IL1A gene was not associated
with AD risk.102 No association was found between
either the -511C > T, 3953T > C, 3953T > C, -1418T >
C or the 315T > C SNPs of the IL1B gene and
AD.100,102,103
IL4 maps on chromosome 5q31.1. It covers 9.01 kb
on the direct strand. The T allele of -590T > C SNP
was associated with an increased risk of AD in a Japa-
nese population.104 In Caucasians the T allele of IL4
-589C > T SNP was significantly associated with the
development of AD at 24 months of age.105 No asso-
ciation between SNPs (-590T > C and 33T > C) of IL4
and AD was found in a Chinese population.106
IL4R maps on chromosome 16p11.2―12.1. It covers
50.86 kb on the direct strand. Many SNPs (-3112C >
T, -1803T > C, -327C > A, -326A > C and -186G > A) or
haplotypes (α) of the IL4R gene are associated with
AD.107 Seven SNPs (223C > G > T > A, 1199C > A,
1291C > T, 1307T > C, 1727G > A, 2356C > T) and a si-
lent 1242T > G have been demonstrated to have func-
tional significance. Caucasian children with the rare
homozygous 1727G > A polymorphism had a higher
prevalence of flexural eczema in the first 6 months
compared with the heterozygote and the wild type
homozygote genotypes combined.108 It has been
demonstrated that the 1727G > A SNP was signifi-
cantly associated with AD in another Japanese popu-
lation.109 No association between SNPs (1199C > A,
1242T > G, 1507C > T and 1727G > A) of IL4R and AD
was found in a Chinese population, however.106
IL5 maps on chromosome 5q31.1. It covers 2.08 kb
on the reverse strand. The -703C > T SNP of IL5 was
not significantly associated with AD in Japanese.110
IL6 maps on chromosome 7p21. It covers 6.12 kb
on the direct strand. No association was found be-
tween the -174C > G SNP of the IL6 gene and AD.100
Similarly, the -174C > G and -922A > G SNPs were not
linked to AD.102
IL10 maps on chromosome 1q31―q32. It covers
4.89 kb on the reverse strand. The -1082A > G,
-819T > C and -592A > C SNPs of the IL10 gene did
not contribute to the development of AD.106 No asso-
ciation was found between AD and the -1082A > G
SNP of the IL10 gene.100 Also, -571C > A, -854C > T
and -1117G > A SNPs of the IL10 gene were not asso-
ciated with AD.102
IL12B maps on chromosome 5q31.1―q33.1. It cov-
ers 15.69 kb on the reverse strand. The AA genotype
of IL12B 1188A > C SNP was associated with de-
creased risk of AD in a Japanese population (OR =
0.44, 95% CI = 0.20―0.95).111 The 4237 G > A, 4496A >
G and 4510G > A SNPs of the IL12B gene did not
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contribute to the development of AD.106
IL12RB1 maps on chromosome 19p13.1. It covers
39.94 kb on the reverse strand. Among eight SNPs (-
111A > T, -2C > T, 4443C > T, 5970 G > C, 17183T >
C, 17369C > T, 25748T > C and 27637A > T), the TT
genotype of the -111A > T SNP (OR = 2.39, 95% CI =
1.41―4.04) and the TT genotype of the -2C > T SNP
(OR = 2.55, 95% CI = 1.43―4.57) were significantly as-
sociated with an increased risk of AD in a Japanese
population.112
IL13 maps on chromosome 5q31. It covers 4.85 k
on the direct strand. No association between the
-1111C > T SNP of IL13 and AD was found in a Chi-
nese population.106 The statistically significant asso-
ciation between the -1024C > T SNP of the IL13 gene
and AD was confirmed.113 In the Japanese population
there was no significant association between two
SNPs of 704A > C and 1103C > T while the Arg allele
of Arg144Gln SNP was significantly associated with
an increased risk of AD.114 A significant association
was noted for the A allele of the Arg144Gln SNP and
AD (OR = 1.77, 95% CI = 1.06―2.96).115 In Caucasians,
haplotypes consisting of IL13 Arg144Gln with AD
(P = 0.006) were associated with AD.105 None of the
three SNPs (-1111C > T, 1293C > T, and Arg144Gln)
were associated with AD during the first year.102
IL18 maps on chromosome 11q22.2―q22.3. It cov-
ers 21.61 kb on the reverse strand. Among five SNPs
(-132A > G, -133C > G, -137G > C, -113T > G and 127C
> T), the C allele of the -137G > C SNP was associated
with an increased risk of AD (OR = 4.28, 95% CI =
1.24―14.77).116
TGFB1 maps on chromosome 19q13.2. It covers
52.34 kb on the reverse strand. The C allele (a low
TGFβ1 producer allele) of the TGFβ1 915 G > C SNP
was associated with an increased risk of AD (OR =
4.8, 95% CI = 2.4―9.7) while there was no statistical
significant difference in the frequencies of the 869T >
C genotypes.117 No association between AD and the
-590C > T SNP was observed.102
TNFα and TNFβ share a common receptor on tu-
mor cells whose expression is upregulated by
gamma-interferon.118 TNF maps on chromosome
6p21.3. No significant association was found between
-308 G > A SNP of the TNFα gene and AD.103 Nei-
ther -1031T > C, -863C > A, -857C > T, -308G > A nor
-238G > A SNPs of the TNFα gene was associated
with AD in a Chinese population.106 No association
was found between AD and -238G > A and -308G > A
SNPs of the TNFβ gene in a German population.100
Also, the two SNPs were not linked to AD risk in
Americans.102
GM-CSF maps on chromosome 5q31.1. It covers
2.38 kb on the direct strand. The A allele of the -677A
> C SNP in the promoter region of the GM-CSF gene
was associated with an increased risk of AD in the
United Kingdom (OR = 2.3, 95% CI = 1.4―3.6).103 Al-
though -1916T > C SNP was significantly associated
with an increased risk of AD (OR = 1.9, 95% CI = 1.2―
3.1), there was a strong linkage disequilibrium ex-
isted between the -677A > C and -1916T > C SNPs.103
The 3606T > C and 3928C > T SNPs of the GM-CSF
gene was not associated with susceptibility to AD in
Japanese.119 There was strong linkage disequilibrium
between the two polymorphisms.
STAT6 maps on chromosome12q13. It covers
16.79 kb on the reverse strand. There was no asso-
ciation between AD risk and the 2964 G > A SNP of
the STAT6 gene while the 1315-GT repeat allele het-
erozygosity of the dinucleotide repeat in exon 1 (13-,
14-, 15- and 16-GT repeat alleles) was significantly as-
sociated with allergic disease including AD in Japa-
nese.120 However, the short tandem repeat in exon 1
was not associated with AD risk.106
IFNγ maps on chromosome 12q14. It covers 16.25
kb on the reverse strand. In a Chinese population,
there was no association between short tandem re-
peats at the first intron of IFNγ gene and AD.106
ANTIGEN PRESENTATION MOLECULES
The human major histocompatibility complex (MHC,
also called the human leukocyte antigen (HLA) com-
plex) class I molecules are expressed on all human
cells except erythrocytes and trophoblasts. HLA
molecules are peptide-binding proteins on the sur-
faces of antigen-presenting cells. The complex of an
HLA molecule and bound antigenic peptide forms a
specific target for T cell recognition. HLA-A and HLA-
B belong to the HLA class I heavy chain paralogues.
This class I molecule is a heterodimer consisting of a
heavy chain and a light chain. The heavy chain is an-
chored in the membrane. Class I molecules play a
central role in the immune system by presenting pep-
tides derived from the endoplasmic reticulum lumen.
The class I molecules generally present antigens to
CD8+ T cells, and class II molecules present antigens
to CD4+ T cells. They are expressed in nearly all
cells. On the other hand, HLA-DM belongs to the
HLA class II beta chain paralogues. This class II
molecule is a heterodimer consisting of an alpha
(DMA) and a beta (DMB) chain, both anchored in
the membrane. It is located in intracellular vesicles.
HLA-DM plays a central role in the peptide loading of
HLA class II molecules by helping to release the class
II-associated invariant chain peptide molecule from
the peptide binding site. Class II molecules are ex-
pressed in antigen presenting cells such as B lympho-
cytes, dendritic cells and macrophages. Both HLA
class I and class II antigens contribute to the patho-
genesis of AD.121 In antigen presentation to cytotoxic
T cells with HLA class I molecules, the antigen-
processing pathway is controlled by the products of
genes that are mapped within the HLA class I region,
including low-molecular-weight polypeptide (LMP)
and transporters associated with transporter for anti-
gen presentation (TAP). TAP delivers cytosol-derived
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peptides into the endoplasmic reticulum, where they
bind to nascent HLA class I molecules. TAP is com-
posed of two subunits, TAP1 and TAP2; deficiency of
either subunit inhibits TAP function, reducing the
supply and repertoire of peptides available for bind-
ing to HLA class I molecules. Many diseases associ-
ated with HLA have been investigated for the influ-
ence of TAP.122-127 LMP products also have an impor-
tant role in antigen presentation by class I HLA mole-
cules. LMP subunit 2 (LMP2) and LMP7 are protea-
some components, which enhance the proteolytic
production of certain peptides.128,129
The HLA group of genes resides on chromosome
6p21.3. Eleven HLA-A (1, 2, 3, 11, 24, 26, 29, 30, 31, 33
and 66) and 27 HLA-B (7, 8, 13, 14, 16, 27, 35, 37, 38,
39, 46, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
67, 71 and 75) alleles are frequently observed in Ko-
reans. Among these, only the A24 allele of HLA was
significantly associated with AD.130 No HLA-DMA
(Val140Ile, Gly155Ala, Ile179Thr, 184Arg-His-Cys)
and HLA-DMB (144Ala-Glu-Val) alleles were associ-
ated with an increased risk of AD.131
LMP2 (PSMB9) and LMP7 (PSMB8) map on chro-
mosome 6p21.3. LMP2 and LMP7 genes encode two
subunits of the proteasome, a cytoplasmic catalytic
complex involved in the generation of antigenic pep-
tides that are loaded on class I molecules within the
endoplasmic reticulum.132 LMP27 subunits may di-
rectly affect peptide cleavage specificity.128,129 One di-
morphic site within LMP2, Arg60His, and three di-
morphic sites within LMP7, 3911 G > T, 3912C > T,
4069C > T, have been identified. SNPs of LMP2 and
LMP7 genes were not significantly different for AD
patients and controls.130
TAP1 and TAP2 map on chromosome 6p21.3. TAP
genes encode a heterodimer involved in the translo-
cation of intracellular peptides across the endoplas-
mic reticulum membrane where they bind to class I
molecules. Genes encoding the two TAP subunits,
TAP1 and TAP2, are located within the MHC class II
region between the DPB1 and DQB1 loci133,134 and
variations in rat TAP genes have been reported to be
associated with differences in the spectrum of MHC
class I-binding peptides.135 TAP1 and TAP2 genes are
located at 6p21.3. Two dimorphic sites within TAP1,
Val333Ile and Gly637Asp, and four dimorphic sites
within TAP2, Ile379Val, Thr565Ala, Ala665Thr and
Gln687Stop, have been widely investigated.134 The
333Val and 637Gly alleles of the TAP1 gene were sig-
nificantly associated with an increased risk of AD in
Tunisians136 while allelic frequencies of the TAP1
gene polymorphisms were similar in AD patients and
controls.130 The 565Ala and 665Thr alleles of the
TAP2 gene may be associated with increased risk of
AD in a Korean population.130
OTHER MOLECULES
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA4,
also known as CD152) is a member of the Ig gene su-
perfamily along with its homologue, CD28, a B7 bind-
ing protein.137,138 CTLA4 is an inhibitory molecule
that downregulates T-cell activation. Thus, ligation of
CTLA4 on the T-cell surface initiates a cascade of bio-
chemical events that attenuate an ongoing immune
response.139 Allergic diseases are characterized by a
defective peripheral T cell tolerance to allergens, sug-
gestive of possible CTLA4 dysfunction.140,141
Kallikrein (KLK, stratum corneum chymotryptic
enzyme (SCCE)) localizes to the extracellular space
of the stratum corneum and is specific for keratiniz-
ing cells undergoing desquamation.142-145 KLK
(SCCE) is secreted as an inactive zymogen that is ac-
tivated by cleavage of an N-terminal peptide. Physi-
ological activators of zymogens remain unknown but
in vitro studies indicate that some kallikreins can un-
dergo autoactivation while others may be activated by
other kallikreins or endoproteases. Apart from its tis-
sue localization, KLK (SCCE) has several properties
and characteristics, including the pH and inhibitor
profile of catalytic activity, matching the basic pre-
requisites for a crucial involvement in desquamation
under in vivo conditions.143,146,147 Transgenic mice
overexpressing human KLK (SCCE) develop chan-
ges in their skin similar to those seen in chronic
atopic dermatitis.148 The overexpression of KLK
(SCCE) initially may lead to a premature breakdown
of the epidermal barrier. This would allow the pene-
tration of irritants and allergens, triggering an inflam-
matory response, and subsequently a reactive hyper-
plasia. Therefore KLK (SCCE) is considered to be im-
portant in the pathogenesis of AD.
SLC9AR1 (solute carrier family 9, isoform 3 regula-
tory factor 1) is found in keratinocytes within the
granular layer of the epidermis in normal skin and in
T-cells and has been implicated in diverse aspects of
epithelial membrane biology and immune synapse
formation in cells. The downregulation of SLC9A3R1
after T-cell activation is consistent with its role as a
negative regulator. SLC9A3R1 could have a similar
role in the normal epidermis by modulating the
keratinocyte response to a similar immune signal.
NAT9 is also found in keratinocytes and T-cells and
may play a role in glycosylation. Loss of RUNX1 bind-
ing has been shown to be associated with susceptibil-
ity to autoimmune diseases such as systemic lupus
erythematosus.149 RUNX1 is involved in CD4 silenc-
ing.150 CD4 repression attributed to a RUNX1 muta-
tion was found in only 18―30% of mature CD8+ T lym-
phocytes.150 SNPs lying between SLC9A3R1 and
NAT9 result in the loss of a RUNX 1 binding site.151
The loss of RUNX1 sites in alleles associated with
autoimmune diseases suggest an important role for
RUNX1 in tolerance. It may also suggest defective
regulation of SLC9A3R1 or NAT9 by RUNX1 as a sus-
ceptibility factor for AD.
Serine protease inhibitor, Kazal-type, 5 (SPINK5) is
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thought to be cleaved by furin to yield at least 14 in-
dependently working serine protease inhibitory do-
mains.152,153 Since SPINK5 and many tissue KLKs co-
localize in the skin (in lamellar bodies of the upper-
most epidermis and the pilosebaceous units of nor-
mal human skin tissue),154 it has been hypothesized
that these proteins may be part of a proteolytic
enzyme-inhibitor system that controls skin desqua-
mation and shedding.152,154
CTLA4 maps on chromosome 2q33. It covers 5.55
kbon the direct strand. CTLA4 is linked to an in-
creased incidence of autoimmune diseases.155 A SNP
at position 49 in exon 1 (49A > G) of CTLA4 exerts
differential functional effects on CTLA4 driven down-
regulation of T-cell activation.156-158 The 49A > G SNP
leads to a threonine to alanine change in the lead pep-
tide. The 49A > G SNP of CTLA4 gene was not corre-
lated with AD, however.159
KLK7 gene maps on chromosome 19q13.33. It cov-
ers 7.57 kb on the reverse strand. Among all serine
proteases within the human genome, the tissue KLK
(SCCE) cluster is the largest. This cluster includes fif-
teen genes tandemly located on chromosome
19q13.4. KLKs generally share 30―50% sequence
identity at the nucleotide and amino-acid levels.160
The KLK5 and KLK7 genes were originally identified
from a keratinocyte library and their products were
first named human stratum corneum tryptic enzyme
(hK5)161 and human stratum corneum chymotryptic
enzyme (hK7).162 These KLKs seem to catalyze the
degradation of intercellular structures in the most
cornified layer of the skin and contribute to the nor-
mal cell shedding process at the skin surface.163,164
KLK5 and KLK7 have been implicated in skin and
brain diseases.160,165,166 Recent studies have also re-
vealed alterations of their expression in hormone-
dependent cancers.167-169 A 4-bp insertion was identi-
fied in the 3’ untranslated region of the KLK7 (SCCE)
gene. The common allele was AACC, and the rare al-
lele was AACCAACC. A significant genetic associa-
tion was found between the rare AACCAACC variant
of the KLK7 (SCCE) gene and AD.170
Both SLC9A3R1 and NAT9 map on chromosome
17q25.1. The RUNX1 gene maps on chromosome
21q22.3. A SNP is located between the SLC9A3R1
and NAT9 genes in chromosome segment 17q25.
This SNP occurs within a consensus binding site mo-
tif for RUNX1, a factor required for both differentia-
tion and proliferation of haematopoietic cells. There
was no significant allelic association between the
RUNX1 polymorphism (rs734232) and AD in a small
Japanese adult population.171
The serine protease inhibitor Kazal type 5 gene
(SPINK5) expresses the 15 domain serine protease
inhibitor lymphoepithelial Kazal-type-related inhibi-
tor, named LEKTI.172 SPINK5 is located on chromo-
some 5q32 within a genomic region that has previ-
ously been linked to AD by a genome-wide linkage
study and, consequently, SPINK5 has been impli-
cated as a putative susceptibility gene for common,
nonsyndromic AD.173 Subsequently, Walley et al. re-
ported a significant association of a nonsynonymous
SNP located in exon 14 of SPINK5, consisting of a G-
to-A transition (1258G > A) that leads to a Glu420Lys
substitution in the encoded protein. In individuals af-
fected by AD, a significant maternal over-trans-
mission of the risk allele to their children was demon-
strated.173 Fölster-Holst et al.174 studied 8 SNPs in dif-
ferent regions of the SPINK5 gene, including 4 non-
synonymous SNPs leading to an amino acid change
(Asp106Asn, Asn368Ser (1103A > G) and Asp386Asn
(1156G > A), and Glu420Lys (1258G > A), Gly463Gly,
Val553Val, Leu756Leu and Gly804Gly). None of the
SNPs were associated with an increased risk of AD.
Kato et al. examined associations between 8 SNPs
(IV12-26C > T, IVS12-10A > G, IVS14 + 19 G > A, IVS
13-50 G > A, 1103A > G, 1156 G > A, 1188T > C,
1258G > A) of the SPINK5 gene and AD in a Japanese
population and found a positive association of 7
SPINK5 SNPs (except for 1156G > A) with AD.175
Nishio et al.176 also reported a significant association
between SPINK5 1258G > A and AD risk. No statisti-
cally significant association between SPINK5
1258G > A genotypes and AD was observed in a large
German population.177
DRUG-METABOLIZING ENZYMES
The picture of drug-metabolizing enzymes is compli-
cated, because AD is polygenic in nature, and suscep-
tibility is also influenced markedly by environmental
factors. In addition, evidence is emerging that certain
metabolic polymorphisms may influence the patho-
genesis of allergy. The metabolism of xenobiotics in-
cludes oxidation, reduction, and hydrolysis (phase I)
and conjugation (phase II) reactions.178,179 Glu-
tathione S-transferase (GST) enzymes belong to the
phase II detoxification system and are responsible for
biotransformation and degradation of certain electro-
philic compounds. Oxidative stress, with the forma-
tion of reactive oxygen species (ROS), is a key com-
ponent of inflammation.180 Members of the GST su-
pergene family are critical for protecting cells from
ROS because they can utilize a wide variety of prod-
ucts of oxidative stress as substrates and also influ-
ence the synthesis of eicosanoid-like mediators via
modulation of ROS levels.181,182
N-acetyltransferase (NAT) is one of the conjuga-
tion enzymes and transfers acetate from acetyl coen-
zyme A to the functional groups of primary arylamine
and hydrazine to form acetamides and hydrazides, in
xenobiotics, containing arylamine and hydrazine
groups178,179,183 NAT enzymes, NAT1 and NAT2, are
involved in the metabolism of these carcinogens via
O- and N- acetylation.184 Therefore, NAT2 and NAT1
are involved in the detoxification and bioactivation of
carcinogens.185,186 Individuals in a population are
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either rapid or slow acetylators, depending on their
ability to acetylate certain NAT substrates. Generally,
acetylation is bimodally distributed in different popu-
lations. An association between NAT2 slow acetyla-
tion and allergic diseases and extrinsic asthma in pa-
tients with atopic characteristic has been re-
ported.187,188
Certain genes within the GSTM, GSTT and GSTP
subfamilies (GSTM1, GSTT1 and GSTP1) are poly-
morphic in humans and the levels of individual en-
zymes expressed can be influenced by induction and
genetic polymorphism. The GSTM1, GSTT1 and
GSTP1 genes are located on chromosomes 1p13.3,
22q11.23 and 11q13, respectively. Lack of GSTM1
and GSTT1 activity is caused by the homozygous de-
letion of these intact genes (the null genotype). The
non-null genotype is the wild type or heterozygote.
The 1404A > G (Ile105Val) and 2294C > T (Ala114
Val) SNPs of the GSTP1 gene confers lower levels of
enzyme activity toward a variety of carcinogens and
anticancer agents. As compared with the combined
GSTM1 non-null genotype (GSTT1 non-null genotype
and GSTP1 AG), the combined GSTM1 null genotype
(GSTT1 null genotype and GSTP1 AA) was associ-
ated with a significantly increased risk of AD (OR =
9.43, 95% CI = 1.06―438.6).189
NAT2 gene maps on chromosome 8p23.1―p21.3. It
covers 9.97 kb on the direct strand. N-acetylation is
an important genetic polymorphic pathway in the
biotransformation of one or more single-based muta-
tions in the NAT2 gene known to cause low expres-
sion levels of functional NAT2 enzyme.190,191 Indi-
viduals who carry two slow NAT2 SNPs are slow ace-
tylators, whereas those who are homozygous or het-
erozygous for wild-type NAT2 alleles are rapid ace-
tylators.192,193 The presence of 481C > T, 590 G > A
and 857G > A SNPs would lead to slow acetylation.194
481C > T (synonymous mutation) and 590G > A SNPs
were not related to an increased risk of AD.195 More-
over, 481C > T, 590 G > A and 857G > A, were not as-
sociated with an increased risk of AD.196
DISCUSSION AND CONCLUSION
The most important problems facing AD research are
identifying “at-risk” individuals and implementing
clinical surveillance, prevention practices, and follow-
up care. The immune system plays an important role
in AD. Although the increaseddecreased risk associ-
ated with individual immune system SNPs may be
small compared to that conferred by high-penetrance
cancer genes, their public health implications may be
large because of their high frequency in the general
population. It is thus essential that epidemiological in-
vestigations of immune system polymorphisms are
adequately designed. Unfortunately a fairly large
number of studies are limited by their sample size
and subsequently suffer from lack of power to detect
effects that may truly exist. Also, given the borderline
significance of previously reported associations and
multiple comparisons, it is possible that one or more
findings are false-positives.197 Large and combined
analyses may be preferred to minimize the likelihood
of both false-positive and false-negative results. In ad-
dition, controls should be chosen in such a way that,
if they were cases, they would be included in the case
group; when controls are matched to cases, it is es-
sential to account for matching in the analysis. When
appropriate, confounding factors should be controlled
for, with particular consideration of race and ethnic-
ity.
Continued advances in SNP maps and in high-
throughput genotyping methods will facilitate the
analysis of multiple polymorphisms within genes and
the analysis of multiple genes within pathways. The
effects of polymorphisms are best represented by
their haplotypes. Data from multiple polymorphisms
within a gene can be combined to create haplotypes,
the set of multiple alleles on a single chromosome. A
few studies reviewed here reported haplotype asso-
ciations, although several studies analyzed multiple
polymorphisms within a gene, sometimes with incon-
sistent results. Haplotype analysis can increase the
power to detect disease associations because of
higher heterozygosity and tighter linkage disequilib-
rium with disease-causing mutations. In addition,
haplotype analysis offers the advantage of not assum-
ing that any of the genotyped polymorphisms is func-
tional; rather, it allows for the possibility of an un-
genotyped functional variant to be in linkage dise-
quilibrium with the genotyped polymorphisms.198 An
analysis of data from multiple genes within the same
pathway can provide more comprehensive insight
into the studied associations. Such an analysis may
shed light on the complexities of the many pathways
involved in the immune system and AD development,
providing hypotheses for future functional studies.
Because of concerns over inflated type I error rates in
pathway-wide or genome-wide association studies,
methods of statistical analysis seeking to obviate this
problem are under development.199 The ability to in-
clude haplotype information and data from multiple
genes, and to model their interactions, will provide
more powerful and more comprehensive assess-
ments of the immune system.
Although the summary risk for developing AD in
individuals of each genotype may not be large, AD is
such a common disease that even a small increase in
risk can translate to a large number of AD cases.
Therefore, polymorphisms, even those not strongly
associated with AD, should be considered as poten-
tially important public health issues. In addition, it is
important to keep in mind that a susceptibility factor
in one population may not be a factor in another.
There are differences in the prevalence of immune
system polymorphisms across populations. In a popu-
lation where the prevalence of an “at-risk” genotype
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in a given polymorphism is very low, the “at-risk” al-
lele or “at-risk” genotype may be too infrequent to as-
sess its associated risk. At a population level, the at-
tributable risk must be small simply because it is an
infrequent allele. Finally, the major burden of AD in
the population probably results from the complex in-
teraction between many genetic and environmental
factors over time. Many harmful substances in the en-
vironment first require metabolic activation by Phase
I enzymes to their ultimate forms and then the acti-
vated forms are detoxified by Phase II enzymes.200,201
Thus, genetically determined susceptibility to AD
may depend on the balance between drug-metabo-
lizing enzyme activity and immune capacity. Further
investigations of the combined effects of polymor-
phisms between immune response genes and drug-
metabolizing genes may also help to clarify the influ-
ence of genetic variation in the AD development.
Consortia and international collaborative studies,
which may be a way to maximize study efficacy and
overcome the limitations of individual studies, are
needed to help further illuminate the complex land-
scape of AD risk and genetic variations.
The characterization of the genetic factors involved
in this common, chronic disorder may provide impor-
tant clues to its relationship to other diseases, such as
asthma and allergic rhinitis, and is ultimately hoped
to lead to more effective interventional strategies.
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